Bharat Biotech Subsidiary Partners with VeGen Bio to Manufacture CAR-T Therapy
Bharat Biotech's subsidiary Nucelion Therapeutics has partnered with Hyderabad-based VeGen Bio to manufacture VL-2511, an experimental CAR-T therapy targeting multiple myeloma. Nucelion will handle technology transfer, process development, and manufacturing for clinical trials and commercial production, aiming for Phase 1-2 trials in India and potential commercialization by 2028, pending regulatory approval. This collaboration focuses on manufacturing services rather than marketing, with plans to extend the partnership to other cell therapy candidates in VeGen Bio's pipeline.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 42/100.
Outlets measured: thehindu, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 21 Oct, 09:30 am. Other outlets followed.
- 1